Zentalis Pharmaceuticals (ZNTL) Invested Capital (2022 - 2025)
Historic Invested Capital for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to $252.9 million.
- Zentalis Pharmaceuticals' Invested Capital fell 2863.34% to $252.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $252.9 million, marking a year-over-year decrease of 2863.34%. This contributed to the annual value of $337.2 million for FY2024, which is 2290.97% down from last year.
- Per Zentalis Pharmaceuticals' latest filing, its Invested Capital stood at $252.9 million for Q3 2025, which was down 2863.34% from $274.5 million recorded in Q2 2025.
- Over the past 5 years, Zentalis Pharmaceuticals' Invested Capital peaked at $523.3 million during Q2 2023, and registered a low of $252.9 million during Q3 2025.
- Its 4-year average for Invested Capital is $389.0 million, with a median of $385.7 million in 2023.
- In the last 5 years, Zentalis Pharmaceuticals' Invested Capital surged by 2217.5% in 2023 and then plummeted by 3561.45% in 2025.
- Over the past 4 years, Zentalis Pharmaceuticals' Invested Capital (Quarter) stood at $434.0 million in 2022, then grew by 0.78% to $437.4 million in 2023, then fell by 22.91% to $337.2 million in 2024, then fell by 25.0% to $252.9 million in 2025.
- Its last three reported values are $252.9 million in Q3 2025, $274.5 million for Q2 2025, and $295.4 million during Q1 2025.